---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-051900"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-08-03T20:28:16+00:00"
generated_at: "2026-08-03T20:31:23.473533+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Amneal reprices $2.084B term loan, cuts interest margin by 50 bps, saving ~$12M annually

## Summary
- Reduced interest rate margin by 50 bps to 1.50% (base rate) and 2.50% (SOFR) on $2.084B term loans.
- Converted $2.039B existing term loans on cashless basis; added $45.2M new term loan to repay non-converted loans.
- Maturity unchanged at August 1, 2032; no prepayment premium for repricing after February 3, 2027.
- Estimated annualized cash interest savings of approximately $12 million based on outstanding borrowings.

## SEC filing metadata
- accession: 0001628280-26-051900
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-08-03T20:28:16+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000162828026051900/0001628280-26-051900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000162828026051900/amrx-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-051900
- JSON: https://secwatch.observer/filing/0001628280-26-051900.json
- Plain text: https://secwatch.observer/filing/0001628280-26-051900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.